Want to see HK:1696 full AI Analyst Report?
Sisram Medical Ltd. (1696) Stock Price & Analysis
1696 Stock Chart & Stats
- Day’s Range
- HKD 1.77 - HKD 1.88
- 52-Week Range
- HKD 1.71 - HKD 4.91
- Previous Close
- HKD 1.76
- Volume
- N/A
- Average Volume (3M)
- 232.39K
- Market Cap
- HKD 824.28M
- Enterprise Value
- HKD 2.01B
- Total Cash (Recent Filing)
- HKD 77.27M
- Total Debt (Recent Filing)
- HKD 78.87M
- Price to Earnings (P/E)
- 9.3
- Beta
- 0.99
- Next Earnings
- Mar 24, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Aug 26, 2026
- Dividend Yield
- 5.37%
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet
Very low leverage and continued equity growth give Sisram Medical financial resilience and flexibility. A conservative capital structure reduces balance-sheet risk, supports continued investment in products and services, and provides greater capacity to manage fluctuations in demand or profitability.
Recurring Installed-base Revenue
The installed-base model supplements one-time equipment sales with consumables, service, maintenance, and training revenue. As deployed systems are used over time, these recurring streams can improve customer retention, diversify revenue, and make the business less dependent on new capital-equipment purchases.
Revenue Growth And Gross Margin
Multi-year revenue growth indicates that Sisram Medical has continued expanding its business, while a gross margin near 59% shows meaningful economic value remains in its products. This combination can support reinvestment and operating leverage if growth and cost control improve.
Bears Say
Material Margin Compression
The sharp decline in net margin shows that revenue growth is currently converting into substantially less profit than in earlier periods. Higher costs and/or pricing pressure could remain a durable constraint, reducing reinvestment capacity and weakening earnings resilience even if sales continue to expand.
Weakened Cash Generation
The steep 2025 decline in operating and free cash flow indicates weaker cash conversion and reduces internally generated funding for growth, dividends, or investment. Although free cash flow remained positive, the deterioration raises concern that earnings are not translating consistently into available cash.
Declining Earnings Momentum
A substantial decline in EPS, alongside lower return on equity, signals that the company is currently generating less shareholder profit from its capital base. If this persists, it can limit the effectiveness of the strong balance sheet and weaken the sustainability of future earnings growth.
Sisram Medical Ltd. News
Sisram Seeks Independent Shareholder Approval for Renewal of Connected Transactions With Fosun Unit
Sisram Medical Ltd. ( ($HK:1696) ) has provided an announcement. Sisram Medical plans to renew its related-party sublicensing and promotional services arrangements between its subsidiary Sisram Tianjin and Fosun Wanbang
Sisram Medical Extends Connected Distribution and Promotion Deals With Fosun Unit to End-2026
Sisram Medical Ltd. ( ($HK:1696) ) has provided an announcement. Sisram Medical has extended both its New Sublicense Agreement and New Promotional Services Agreements with Fosun Wanbang (Jiangsu) to 31
1696 FAQ
What was Sisram Medical Ltd.’s price range in the past 12 months?
What is Sisram Medical Ltd.’s market cap?
When is Sisram Medical Ltd.’s upcoming earnings report date?
How were Sisram Medical Ltd.’s earnings last quarter?
Is Sisram Medical Ltd. overvalued?
Does Sisram Medical Ltd. pay dividends?
What is Sisram Medical Ltd.’s EPS estimate?
How many shares outstanding does Sisram Medical Ltd. have?
What happened to Sisram Medical Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sisram Medical Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Sisram Medical Ltd. Stock Smart Score
Company Description
Sisram Medical Ltd.
Sisram Medical Ltd, an investment holding company headquartered in Caesarea, Israel, since its establishment in 2013, is engaged in the creation, production, and worldwide distribution of a broad spectrum of medical solutions. The company develops and markets energy-based aesthetic devices, minimally invasive therapeutic systems, non-energy-dependent equipment, and cosmeceuticals, reaching markets across Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa. Its comprehensive range of products and treatments addresses numerous conditions, such as hair removal, skin revitalization, acne and scarring, body and facial sculpting, pigment and skin surface refinement, fat transfer procedures, injectable dermal fillers, skin tissue regeneration injectables, personal wellness items, cosmetic dental procedures, transdermal delivery methods, cellulite reduction, stretch mark amelioration, therapy for vascular and pigmented lesions, hydradermabrasion, non-surgical eyelid lifts (blepharoplasty), liposuction, as well as feminine health and sexual well-being applications. Furthermore, the company is involved in the manufacturing, distribution, and sales of general medical apparatus. Sisram Medical's offerings are available under its prominent brand names, which include Alma, Soprano, Harmony, Copulla, Foshion, Accent, and LMNT.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jiahong Li
- Employees
- 1,043
- Website
- www.sisram-medical.com
- Address
- Ofek Building 15, Caesarea, HA, 3079895, IL
Sisram Medical Ltd. (1696) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 5 | 12 |
| Technical Analysis | 5 | 5 | 0 |
| Moving Averages | 0 | 0 | 12 |









